Yukihiko Hiroshima1, Ali Maawy2, Yong Zhang3, Takashi Murakami4, Masashi Momiyama4, Ryutaro Mori4, Ryusei Matsuyama4, Takashi Chishima4, Kuniya Tanaka4, Yasushi Ichikawa4, Itaru Endo4, Robert M Hoffman5, Michael Bouvet6. 1. AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California San Diego, San Diego, CA, USA; Yokohama City University Graduate School of Medicine, Yokohama, Japan. 2. Department of Surgery, University of California San Diego, San Diego, CA, USA. 3. AntiCancer, Inc., San Diego, CA, USA. 4. Yokohama City University Graduate School of Medicine, Yokohama, Japan. 5. AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California San Diego, San Diego, CA, USA. 6. Department of Surgery, University of California San Diego, San Diego, CA, USA. Electronic address: mbouvet@ucsd.edu.
Abstract
BACKGROUND: The aim of this study is to determine the efficacy of neoadjuvant chemotherapy (NAC) with gemcitabine (GEM) in combination with fluorescence-guided surgery (FGS) on a pancreatic cancer patient derived orthotopic xenograft (PDOX) model. METHODS: A PDOX model was established from a CEA-positive tumor from a patient who had undergone a pancreaticoduodenectomy for pancreatic adenocarcinoma. Mice were randomized to 4 groups: bright light surgery (BLS) only; BLS + NAC; FGS only; and FGS + NAC. An anti-CEA antibody conjugated to DyLight 650 was administered intravenously via the tail vein of mice with a pancreatic cancer PDOX 24 h before surgery. RESULTS: The PDOX was clearly labeled with fluorophore-conjugated anti-CEA antibody. Only one out of 8 mice had local recurrence in the FGS only group and zero out of 8 mice had local recurrence in the FGS + NAC which was significantly lower than BLS only or BLS + NAC mice, where local disease recurred in 6 out of 8 mice in each treatment group (p = 0.041 and p = 0.007, respectively). NAC did not significantly reduce recurrence rates when combined with either FGS or BLS. CONCLUSION: These results indicate that FGS can significantly reduce local recurrence compared to BLS in pancreatic cancer resistant to NAC.
BACKGROUND: The aim of this study is to determine the efficacy of neoadjuvant chemotherapy (NAC) with gemcitabine (GEM) in combination with fluorescence-guided surgery (FGS) on a pancreatic cancerpatient derived orthotopic xenograft (PDOX) model. METHODS: A PDOX model was established from a CEA-positive tumor from a patient who had undergone a pancreaticoduodenectomy for pancreatic adenocarcinoma. Mice were randomized to 4 groups: bright light surgery (BLS) only; BLS + NAC; FGS only; and FGS + NAC. An anti-CEA antibody conjugated to DyLight 650 was administered intravenously via the tail vein of mice with a pancreatic cancer PDOX 24 h before surgery. RESULTS: The PDOX was clearly labeled with fluorophore-conjugated anti-CEA antibody. Only one out of 8 mice had local recurrence in the FGS only group and zero out of 8 mice had local recurrence in the FGS + NAC which was significantly lower than BLS only or BLS + NACmice, where local disease recurred in 6 out of 8 mice in each treatment group (p = 0.041 and p = 0.007, respectively). NAC did not significantly reduce recurrence rates when combined with either FGS or BLS. CONCLUSION: These results indicate that FGS can significantly reduce local recurrence compared to BLS in pancreatic cancer resistant to NAC.
Authors: Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick Journal: Nat Protoc Date: 2009-10-29 Impact factor: 13.491
Authors: Ali A Maawy; Yukihiko Hiroshima; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Biomed Opt Date: 2013-12 Impact factor: 3.170
Authors: Matthew H G Katz; Jason B Fleming; Priya Bhosale; Gauri Varadhachary; Jeffrey E Lee; Robert Wolff; Huamin Wang; James Abbruzzese; Peter W T Pisters; Jean-Nicolas Vauthey; Chusilp Charnsangavej; Eric Tamm; Christopher H Crane; Aparna Balachandran Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Cristina A Metildi; Sharmeela Kaushal; Chanae R Hardamon; Cynthia S Snyder; Minya Pu; Karen S Messer; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2012-05-24 Impact factor: 6.113
Authors: Matthew H G Katz; Gauri R Varadhachary; Jason B Fleming; Robert A Wolff; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Charlotte C Sun; Huamin Wang; Christopher H Crane; Jeffrey H Lee; Eric P Tamm; James L Abbruzzese; Douglas B Evans Journal: Ann Surg Oncol Date: 2010-02-17 Impact factor: 5.344
Authors: Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-02-06 Impact factor: 5.344
Authors: Kristina L Go; Daniel Delitto; Sarah M Judge; Michael H Gerber; Thomas J George; Kevin E Behrns; Steven J Hughes; Andrew R Judge; Jose G Trevino Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Yukihiko Hiroshima; Thinzar M Lwin; Takashi Murakami; Ali A Mawy; Tanaka Kuniya; Takashi Chishima; Itaru Endo; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454
Authors: Takashi Murakami; Shukuan Li; Qinghong Han; Yuying Tan; Tasuku Kiyuna; Kentaro Igarashi; Kei Kawaguchi; Ho Kyoung Hwang; Kentaro Miyake; Arun S Singh; Scott D Nelson; Sarah M Dry; Yunfeng Li; Yukihiko Hiroshima; Thinzar M Lwin; Jonathan C DeLong; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman Journal: Oncotarget Date: 2017-05-30
Authors: Antonio Barbieri; Sabrina Bimonte; Giovanna Loquercio; Domenica Rea; Marco Cascella; Annamaria Anniciello; Antonio Luciano; Giuseppe Palma; Gaetano Di Costanzo; Azzaro Rosa; Pasquale Giuliano; Claudio Arra Journal: Infect Agent Cancer Date: 2019-08-28 Impact factor: 2.965